國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Hepatitis C virus treatmenthighly ef...

Chayama, Kazuaki.

Hepatitis C virus treatmenthighly effective therapy with direct acting antivirals and associated viral resistance /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Hepatitis C virus treatmentedited by Kazuaki Chayama.
其他題名:	highly effective therapy with direct acting antivirals and associated viral resistance /
其他作者:	Chayama, Kazuaki.
出版者:	Singapore :Springer Singapore :2017.
面頁冊數:	vii, 75 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Hepatitis CTreatment.
電子資源:	http://dx.doi.org/10.1007/978-981-10-2416-0
ISBN:	9789811024160$q(electronic bk.)

Hepatitis C virus treatmenthighly effective therapy with direct acting antivirals and associated viral resistance /
Hepatitis C virus treatmenthighly effective therapy with direct acting antivirals and associated viral resistance /[electronic resource] :edited by Kazuaki Chayama. - Singapore :Springer Singapore :2017. - vii, 75 p. :ill., digital ;24 cm.

This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.

ISBN: 9789811024160$q(electronic bk.)

Standard No.: 10.1007/978-981-10-2416-0doiSubjects--Topical Terms:

558961
Hepatitis C
--Treatment.

LC Class. No.: RC848.H425

Dewey Class. No.: 616.3623

Hepatitis C virus treatmenthighly effective therapy with direct acting antivirals and associated viral resistance /
LDR:02330nmm a2200301 a 4500 001 505862
003 DE-He213
005 20161101043346.0
006 m d
007 cr nn 008maaau
008 171030s2017 si s 0 eng d
020 $a 9789811024160$q(electronic bk.)
020 $a 9789811024153$q(paper)
024 7 $a 10.1007/978-981-10-2416-0 $2 doi
035 $a 978-981-10-2416-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC848.H425
072 7 $a MJJ $2 bicssc
072 7 $a MED031000 $2 bisacsh
082 0 4 $a 616.3623 $2 23
090 $a RC848.H425 $b H529 2017
245 0 0 $a Hepatitis C virus treatment $h [electronic resource] : $b highly effective therapy with direct acting antivirals and associated viral resistance / $c edited by Kazuaki Chayama.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2017.
300 $a vii, 75 p. : $b ill., digital ; $c 24 cm.
520 $a This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.
650 0 $a Hepatitis C $x Treatment. $3 558961
650 0 $a Hepatitis C virus. $3 274259
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Hepatology. $3 274979
650 2 4 $a Virology. $3 196498
650 2 4 $a Drug Resistance. $3 338425
700 1 $a Chayama, Kazuaki. $3 771458
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-2416-0
950 $a Medicine (Springer-11650)